- Supported by leading healthcare specialist and VC investors
- Allegro prepares for clinical trial with hydrocelin osteoarthritis treatment in 2026
Allegro updated this press release on April 20, 2026, to refine certain statements in accordance with regulatory guidelines
Liege, Belgium – 3 July 2025 – Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, has successfully raised €2 million in new funding, showing the strong commitment of core investors to develop hydrocelin as a non-invasive investigational treatment concept under evaluation for potential disease-modifying properties for osteoarthritis. Allegro will use the proceeds of the funding round to prepare hydrocelin for a feasibility study in patients with osteoarthritis in 2026.
Participants in the financing round were Annie Vereecken, a member of Allegro’s Board of Directors where she represents Heran B.V., a leading biotech investor; Noshaq S.A., a specialized life sciences investment manager from Liege, Jürgen Ingels, a Belgian serial entrepreneur and the founder of Smartfin, a leading European venture capital investor, and Piet Van Waes, partner at Belgian investment company Tilleghem.
“I am grateful for the trust in Allegro’s mission that our investors are showing with this capital commitment, which enables us to prepare hydrocelin for a feasibility study next year. We are working hard to provide patients with a potentially disease-modifying, minmally-invasive treatment for osteoarthritis, a prevalent disease for which there are limited effective non-invasive therapeutic options today,” said Lucas Decuypere, Chief Executive Officer of Allegro.
Allegro’s hydrocelin contains cross-linked microparticles that are designed to act as tiny shock absorbers in the synovial fluid of joints affected by osteoarthritis. Restoring the shock-absorbing capacity of the synovial fluid is intended to provide pain relief and protect cartilage. The product is designed to be administered by injection once yearly. In April, Allegro presented positive preclinical data demonstrating the satisfactory safety profile of hydrocelin at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO) in Rome. In addition to this pyrogenicity study, the company has found a satisfactory safety record in preclinical studies assessing irritation, delayed sensitization and systemic toxicity. In February, the company was awarded the Companion Animals Prize from more than 160 applicants at the prestigious Animal Health Europe 2025 Conference (AHNTI) in London.
About Allegro NV
Allegro is a private biomedical company developing transformative treatments for degenerative joint diseases based on its proprietary nanotechnology platform, INTRICATE. The company’s lead product candidate, hydrocelin (ALG-001), is a potential first-in-class, disease-modifying candidate for the treatment of osteoarthritis.
For more information please visit www.allegro.bio.
For further information please contact:
| Allegro NV Lucas Decuypere Chief Executive Officer email info@alllegro.bio | Investor Relations Mary-Ann Chang Cohesion Bureau +44 7483 284 853 mary-ann.chang@cohesionbureau.com Media Relations Douwe Miedema Cohesion Bureau +352 621 562 764 douwe.miedema@cohesionbureau.com |
Important information
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes”, “estimates,” “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company’s actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.